Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level

NCT07649525 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1226

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma (MM)
Plasma Cell Leukemia (PCL)

Interventions

DRUG: Daratumumab
DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: Teclistamab
DRUG: Talquetamab

Sponsor

University of Leeds

Collaborators

[object Object]
[object Object]
[object Object]